This dose-dependent increase in plasma CXCL12 upon ACKR3 blockade correlated with reduced disease severity in an experimental autoimmune encephalomyelitis (EAE) model, an auto-immune model of MS [6]. Here, ACKR3 is linked to myeloid sarcoma.